| Erythropoietin is a promising neuroprotective drug for preterm infants, and treatment with repeated low-dose recombinant human erythropoietin (rhEPO) is well-tolerated. |
| Treatment with repeated low-dose rhEPO improved poor outcomes in preterm infants with intraventricular hemorrhage. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.